Specifications for biotechnology-derived protein drugs

被引:10
作者
Seamon, KB [1 ]
机构
[1] Immunex Corp, Drug Dev, Seattle, WA 98101 USA
关键词
D O I
10.1016/S0958-1669(98)80067-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Specifications are the regulatory and legal standards that a product must meet to be suitable for use in humans. Specifications evolve in parallel with drug development and are refined prior to marketing authorization and, in some cases, after marketing. Recent changes in regulatory procedures for biotechnology-derived protein products have placed much emphasis on the use of characterization and final product specifications to provide assurance of overall quality of these products. In addition, harmonized guidelines for the testing and specifications for biotechnology products have been developed through the international Conference on Harmonization process. The availability of sensitive, quantitative, and specific analytical methods for characterization has made this possible, thus providing regulatory flexibility in the development of biotechnology-derived protein products. Further refinement of these analytical tools will undoubtedly enhance this regulatory flexibility.
引用
收藏
页码:319 / 325
页数:7
相关论文
共 19 条
[1]  
Bader F, 1998, BIOPHARM-APPL T BIO, V11, P20
[2]  
BROWN F, 1997, DEV BIOL STANDARDIZA, V91
[3]   2ND DERIVATIVE INFRARED-SPECTROSCOPY AS A NONDESTRUCTIVE TOOL TO ASSESS THE PURITY AND STRUCTURAL INTEGRITY OF PROTEINS [J].
BYLER, DM ;
WILSON, RM ;
RANDALL, CS ;
SOKOLOSKI, TD .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :446-450
[4]  
CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115
[5]  
HARRIS RJ, 1993, BIO-TECHNOL, V11, P1293
[6]  
*INT C HARM, Q5D DER CHAR SUBSTR
[7]  
*INT C HARM, Q6C STAB TEST BIOT B
[8]  
*INT C HARM, Q6B SPEC NEW DRUG SU
[9]  
*INT C HARM, Q5A QUAL BIOT PROD V
[10]  
*INT C HARM, Q5B AN EXPR CONSTR C